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in the population of patients suffering from bronchial asthma accurate diagnosis should 
precede an appropriate and proportional access 
to medications. current european respiratory 
Society (erS) and american Thoracic Society 
(aTS), and GiNa guidelines for severe asthma1-3 
recommend as first choice high dose inhaled 
corticosteroids (icS) and long-acting broncho-
dilators (long-acting beta-2 agonists [LaBa] 
with/without long acting muscarinic antagonist 
[LaMa]) or as alternatives, leukotriene modi-
fiers, theophylline as controller according to the 
patient’s severity.1-3 combination treatment with 
some of these agents and, and in particular icS, 
LaBa, and LaMa, now available in a single 
inhaler,4 may be required to put and maintain 
control disease in severe asthmatics. even if in a 
small but clinically demanding patients, particu-
larly allergic or with type-2 profile, new biologic 
therapies may be required.5
insights of asthma and severe asthma have 
improved over the last years, following the ap-
plication of precision medicine as the driving 
approach.5 Notwithstanding, much more knowl-
edge gap still remains to fill both in terms of bi-
ology and immunology throughout the course of 
the disease, which includes matching appropri-
ate therapies with specific phenotypes and endo-
types.
The most important advance over the last 20 
years is the better understanding of severe asthma 
not as a continuum worsening starting from mild 
asthma, but as a different disease entity,1, 3, 5, 6 to 
be phenotyped beyond the classical identifica-
tion of reversible respiratory symptoms/airway 
obstruction and bronchial hyperresponsive-
ness.7 This has led scientific community to bet-
ter identify and define what severe asthma is, i.e. 
“asthma which requires treatment with high dose 
corticosteroids (cSs), plus a 2nd controller, to 
remain controlled or which remains uncontrolled 
despite this therapy.”1, 3
Despite improvement in definition, prevalence 
of severe asthma remains undefined with only 
rough and variable estimates (5% to 10%) among 
all the asthmatics individuals,6, 8 with a clear pre-
dominance in the early childhood or mid-adult-
hood.9 This uncertainty relies on the possible gap 
between clinical or physiological confirmation 
(current or previous reversible airway obstruc-
tion with spirometry or methacholine challenge), 
and biologic testing such as biomarkers for type 
2 (T2) inflammation, blood/sputum eosinophils, 
nitric oxide fraction (FeNO), in exhaled air, se-
rum ige antibodies,10 or other biomarkers of au-
toimmunity for differential diagnosis,11 and even 
the treatment adherence or symptoms control.12
Most important, an accurate phenotypic/endo-
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a narrative review on the epidemiology of severe 
asthma and international registries. ricciardolo 
et al.,19 from Turin, italy, and Malta, are present-
ing a systematic review on asthma phenotypes/
endotypes. Biddiscombe and Usmani,20 from 
London, UK, offer an overview of delivery and 
compliance with inhaled therapy in asthma. 
edris and Lahousse21 from Ghent, Belgium, have 
systematically reviewed all papers on the use of 
monoclonal antibodies to treat type 2 asthma. 
correia-de-Sousa et al.,22 from Portugal, are 
tackling the management of asthma in primary 
health care. Lastly, Bosi et al.,23 from Modena, 
italy, investigated the management of critically 
ill asthma attacks.
The general aim with this series is to high-
light the main key points that actually drive the 
most appropriate management of patients with 
bronchial asthma and severe asthma in particu-
lar. We are confident that the series’ content will 
enable readers to update information in order to 
translate knowledge into a best practice for spe-
cialists and even for current practitioners. With 
regard to this, in particular, a special focus was 
placed on how to manage asthmatic individuals 
in the primary care, including treatment compli-
ance, which is one of the pivotal aspect that has 
been reported recently by a joint european task 
force.24
as for the premises above, large room was 
given to the most relevant aspect dealing with 
the patient’s phenotyping and the advanced per-
sonalized therapy offered by the available mono-
clonal antibodies pointing out their expanded 
role with the syndromic aspects of the disease in 
adults. Last, but not least, a specific focus and at-
tention on the acute asthma attack has been given 
since still several individuals come to emergency 
unaware of this risky condition to their life.
Overall, this series of reviews would like to 
raise awareness on a very serious condition, 
namely bronchial asthma, which is still underes-
timated for its consequences. in particular, inte-
grating approach in those patients not controlled 
should prompt a better understanding of a pos-
sible specific phenotype, in relation to important 
biological/immunological/genetic pathways and 
clinical characteristics such as age, onset, and 
other clinical features.
typic diagnostic assessment also requires search 
and management of comorbidities (e.g. sinus 
disease, nasal polyps, gastro-esophageal reflux, 
atopic dermatitis, etc.) which is nowadays es-
sential in order to best match asthma profile with 
the therapeutic options that actually include bio-
logic medications.13 To this scope, the Unbiased 
Biomarkers for the Prediction of respiratory 
disease Outcomes (U-BiOPred) study has de-
fined strategies to accurately assess the T2 phe-
notyping of asthma patients.14 However, little is 
known about the trajectories of these identifiable 
phenotypes based on monitoring both the clini-
cal and biological characteristics. Similarly, no 
definitive conclusions are still available about 
the predictive role of any of these biomarkers, 
once assessed earlier, in terms of the disease 
course.15
To date there are five registered and available 
biologic therapies for patients with severe asth-
ma.5 These approved monoclonal antibodies dif-
fer in patient’s response according to their spe-
cific targets and have shown efficacy in response 
to an abnormal rise in T2 systemic inflammation 
and/or circulating ige in allergic individuals. 
Remarkably, outside a specific T2 inflammatory 
response, the so called low-T2 asthmatics still 
do not have any definitive response of adequate 
therapies such as biologics or other drugs (i.e. 
azithromycin), nor different physical approaches 
such as bronchial thermoplasty could be widely 
recommended.16 Genetic or molecular mecha-
nisms associated with these phenotypes/endo-
types remain poorly understood.5
Final, and most important on the clinical 
ground, still several patients suffer from sud-
den acute asthma attacks by not responding to 
usual and/or specific biologic therapies. Which 
potentially leads patients to respiratory distress 
and death.17
With this review series published as a journal 
special issue on severe asthma, we aim at updat-
ing the actual knowledge in adult asthma. ex-
perts and opinion leaders were therefore invited 
to contribute to a shared editorial plan. The jour-
nal editor’s choice in this series was to mix-up 
narrative with systematic reviews according to 
the different topics included.
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